33 assets in Mucosal Melanoma

Therapeutic assets addressing Mucosal Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pembrolizumab Mucosal Melanoma	Melanoma Institute Australia	P3	BB (65)
Interferon Alfa-2B Mucosal Melanoma	Shanghai Junshi Bioscience Co., Ltd.	P3	B (63)
Carboplatin Mucosal Melanoma	Sun Yat-sen University	P3	B (62)
Cyclophosphamide Mucosal Melanoma	Melanoma Institute Australia	P3	B (62)
Ipilimumab Mucosal Melanoma	Melanoma Institute Australia	P3	B (62)
Nivolumab Mucosal Melanoma	Fred Hutchinson Cancer Center	P2	B (62)
Poly-Iclc Mucosal Melanoma	Fred Hutchinson Cancer Center	P2	B (62)
Axitinib Mucosal Melanoma	Peking University Cancer Hospital & Institute	P2	B (58)
Relatlimab Mucosal Melanoma	University Health Network, Toronto	P2	B (57)
YH-003 (HUMANIZED AGONISTIC ANTI-CD40 IGG2 MONOCLONAL ANTIBODY) Mucosal Melanoma	Eucure (Beijing) Biopharma Co., Ltd	P2	B (57)
Binimetinib Mucosal Melanoma	SWOG Cancer Research Network	P2	CCC (53)
Cis-Diamminedichloroplatinum Ii Mucosal Melanoma	The First Hospital of Jilin University	P2	CCC (53)
Dacarbazine Mucosal Melanoma	The First Hospital of Jilin University	P2	CCC (53)
Dinaciclib Mucosal Melanoma	National Cancer Institute (NCI)	P2	CCC (53)
Encorafenib Mucosal Melanoma	SWOG Cancer Research Network	P2	CCC (53)
Envafolimab Mucosal Melanoma	Fudan University	P2	CCC (53)
Lenvatinib Mucosal Melanoma	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	P2	CCC (53)
Nemvaleukin Alfa Mucosal Melanoma	Mural Oncology, Inc	P2	CCC (53)
Olaparib Mucosal Melanoma	Dana-Farber Cancer Institute	P2	CCC (53)
Pucotenlimab Mucosal Melanoma	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	P2	CCC (53)
Rivoceranib Mucosal Melanoma	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	P2	CCC (53)
Tuvoraleimab Mucosal Melanoma	Fudan University	P2	CCC (53)
Toripalimab Mucosal Melanoma	Eye & ENT Hospital of Fudan University	P2	CCC (49)
Vactosertib Mucosal Melanoma	Yonsei University	P2	CCC (49)
Apg 115 Mucosal Melanoma	Ascentage Pharma Group Inc.	P1/2	CC (45)
Mdna11 Mucosal Melanoma	Medicenna Therapeutics, Inc.	P1/2	CC (45)
Fludarabine Mucosal Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P1	CC (44)
Tbio-4101 Mucosal Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P1	CC (44)
[225ac]ac-a9-3408 Mucosal Melanoma	Alpha-9 Oncology USA Inc.	P1	CC (41)
Ivonescimab Mucosal Melanoma	Peking University Cancer Hospital & Institute	P1	CC (41)
Kup-101A Mucosal Melanoma	Kupando GmbH	P1	CC (41)
Anti-Pd-L1 Monoclonal Antibody Shr-1316 Mucosal Melanoma	Sun Yat-sen University	P2	NR ()
Cabozantinib Mucosal Melanoma	National Cancer Institute (NCI)	P2	NR ()